Metronidazole Chewable Tablets

1. Uptake by Pathogens

Obligate anaerobic pathogens, including typical pathogenic bacteria such asBacteroides fragilis and Clostridioides difficile, as well as common parasitic protozoa like Trichomonas vaginalis and Giardia lamblia, survive and proliferate exclusively in oxygen-deficient microenvironments such as the abdominal cavity, intestinal tract, necrotic tissues and mucosal cavities. To adapt to hypoxic living conditions, these pathogens have evolved a unique low-redox-potential electron transport system, which is essential for their energy metabolism and substance circulation.

This specific transport system can actively recognize, capture and transport entizol molecules from the extracellular environment into the pathogen interior, achieving efficient intracellular enrichment.Ultimately, the intracellular drug concentration can reach 50–100 times that of human plasma concentration, forming a high-concentration microenvironment sufficient to exert lethal effects on pathogens. In contrast, aerobic and facultative anaerobic bacteria do not possess this specific drug transport and enrichment system due to their reliance on oxygen-dependent metabolic pathways, so they cannot uptake and accumulate entizol. This fundamental metabolic difference endows entizol with a narrow and precise antimicrobial spectrum.

2. Activation via Nitro Group Reduction

Entizol is a prodrug in its original inert state and lacks antimicrobial activity before intracellular activation. After being enriched in pathogen cells, the nitro group (-NO₂) on its molecular structure undergoes a specific reduction reaction catalyzed by endogenous nitroreductase enzymes. Different types of pathogens carry corresponding specific catalytic enzymes: anaerobic bacteria mainly rely on ferredoxin reductase, while protozoa utilize NADPH-dependent reductases to complete the reaction.

This enzymatic reduction converts the inert nitro group into highly active reactive intermediates, with nitro radical anion being the core functional active substance that exerts subsequent lethal effects. Notably, this activation process is strictly oxygen-sensitive. Excess oxygen can competitively inhibit the activity of nitroreductase enzymes and block the reduction of metronidazole chewable tablets, which explains why the drug achieves optimal therapeutic effects in hypoxic and anaerobic lesion sites, including abdominal abscesses, intestinal lumen tissues, and ischemic necrotic wounds. In oxygen-rich normal tissues, the drug is difficult to activate, which further ensures its biological safety to human tissues.

3. DNA Damage and Cell Death

The activated nitro radical anion has strong chemical reactivity and can covalently bind to the double-stranded DNA of pathogens stably and irreversibly. This binding triggers a series of fatal genetic damage effects, including DNA strand breakage, molecular cross-linking, and abnormal base modification, which fundamentally destroy the integrity and stability of the pathogen's genetic material. Human somatic cells are equipped with mature and robust DNA repair systems such as the nucleotide excision repair pathway, which can efficiently identify and repair occasional DNA damage, avoiding cell dysfunction and death.

However, anaerobic bacteria and pathogenic protozoa have simple genetic structures and incomplete metabolic repair mechanisms, and they lack effective DNA damage repair systems. Once their DNA structure is severely destroyed, they cannot complete self-repair. This irreversible genetic damage directly blocks the normal processes of pathogen DNA replication, gene transcription and protein synthesis, completely inhibiting their growth and reproduction. Ultimately, the pathogens lose their vitality and die, realizing thorough bactericidal and protozoicidal effects-rather than merely inhibiting microbial growth, which ensures a thorough and lasting therapeutic effect.

Metabolism​

The majority of metrolyl (approximately 60% to 80%) is metabolized in the liver by the cytochrome P450 (CYP) enzyme system, primarily by CYP3A4 and CYP2B6. The main metabolite is 2-hydroxymethyl metronidazole, which retains approximately 30% to 50% of the parent drug's antimicrobial activity. Other minor metabolites include metrolyl N-oxide and glucuronide conjugates, which are inactive.​

Liver function plays a critical role in metrolyl metabolism. In patients with moderate to severe hepatic impairment, the clearance of metrolyl is reduced, leading to increased plasma concentrations and a prolonged half-life.

This requires dosage adjustments to avoid drug accumulation and the risk of adverse effects, particularly neurotoxicity. In contrast, patients with mild hepatic impairment do not typically require dosage modifications, as metabolism remains relatively intact.​

In patients with renal impairment, the excretion of metrolyl and its metabolites is reduced. However, because the parent drug is primarily metabolized in the liver, dosage adjustments are only necessary in patients with severe renal impairment (creatinine clearance <30 mL/min) or those undergoing hemodialysis. Hemodialysis removes approximately 50% of the drug from the plasma, so a supplementary dose is often recommended after dialysis to maintain therapeutic concentrations. Peritoneal dialysis has a minimal effect on metrolyl clearance and does not require dosage adjustments.

Entizol inherently possesses excellent lipophilicity. When formulated into chewable tablets, the drug rapidly disperses and dissolves in the oral cavity. It can be absorbed through the gastrointestinal mucosa without complete tablet disintegration, quickly entering the bloodstream and distributing throughout systemic tissues. The agent crosses multiple physiological barriers to achieve extensive tissue distribution. It readily penetrates abscess capsules, periodontal soft tissues, intestinal epithelia and genital tract mucosae, and also infiltrates necrotic, ischemic and hypoxic lesional tissues. Effective therapeutic concentrations can be attained in dense inflammatory lesions that are barely permeable to conventional tablets.

The lesion-targeting property of this preparation relies on the hypoxic microenvironment at infected sites to exert precise therapeutic effects. Lesions such as intra-abdominal abscesses, periodontitis and pelvic infections contain extremely low oxygen levels, supporting massive proliferation of anaerobic bacteria. Such hypoxic conditions activate nitroreductase in pathogenic microorganisms, converting entizol into reactive free radicals that induce DNA damage. In contrast, oxygen present in normal oxygenated tissues inhibits drug activation, leaving only non-toxic parent metronidazole chewable tablets intact without causing injury to healthy human cells.

Compared with conventional oral tablets, chewable tablets disperse at a faster rate and shorten the time to reach peak plasma concentration. They rapidly accumulate sufficient activated drug within anaerobic lesions, combining potent systemic tissue penetration with localized targeted bactericidal activity. This formulation delivers distinctive therapeutic benefits against deep-seated infections caused by various anaerobic bacteria.